TrialSignal
Clinical trial intelligence report
A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT01274533-Jul 28, 2026
NCT ID
NCT01274533
Status
COMPLETED
Phase
PHASE2
Sponsor
Columbia University
Executive brief
Investment-Ready Snapshot
A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma is a PHASE2 clinical asset sponsored by Columbia University in Adult T Cell Leukemia/Lymphoma. SEO and diligence focus: Lenalidomide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01274533
Indication
Adult T Cell Leukemia/Lymphoma
Modality
small molecule
Target
Lenalidomide
Intervention
Lenalidomide
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.